Wednesday, July 8, 2026

Drug profile · INN

eluxadoline

eluxadoline (TRUBERZI) is a mu opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Alimentary tract and metabolism (A07) A07
US status approved
Patents linked 1
Pipeline programs 0
News articles 0
Drug details — eluxadoline
US status
approved
Class
Alimentary tract and metabolism (A07)
Route
ORAL
Patents
1
Programs
0
Data quality
0.84

Quick answer

eluxadoline (TRUBERZI) is a mu opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN eluxadoline
Brand TRUBERZI
Mechanism Mu opioid receptor agonist
Target Mu-type opioid receptor
Therapeutic class Alimentary tract and metabolism (A07)
Route ORAL
Formulation TABLET
ATC code A07

Mechanism of action

Mu opioid receptor agonist

Primary target: Mu-type opioid receptor

Approval history

Authority Status Date
FDA approved
EMA withdrawn

Related & competitor drugs

  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. alvimopan Mu opioid receptor antagonist
  5. aprepitant Alimentary tract and metabolism (A04)
  6. budesonide Alimentary tract and metabolism (A07)

Related patents

  1. US 10314819

    Solid state forms of Eluxadoline

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is eluxadoline?

eluxadoline (TRUBERZI) is a mu opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for eluxadoline?

TRUBERZI is a marketed brand name for eluxadoline. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of eluxadoline?

eluxadoline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.